Einzeltreffer — DigiBib

Purpose: (18)F-Fluoro-L-dihydroxyphenylalanine ((18)F-DOPA) PET offers high sensitivity and specificity in the imaging of nonmetastatic extra-adrenal paragangliomas (PGL) but lower sensitivity in metastatic or multifocal disease. These tumours are of neuroendocrine origin and can be detected by (68)Ga-DOTA-Tyr(3)-octreotide ((68)Ga-DOTA-TOC) PET. Therefore, we compared (68)Ga-DOTA-TOC and (18)F-DOPA as radiolabels for PET/CT imaging for the diagnosis and staging of extra-adrenal PGL. Combined cross-sectional imaging was the reference standard.

Methods: A total of 5 men and 15 women (age range 22 to 73 years) with anatomical and/or histologically proven extra-adrenal PGL were included in this study. Of these patients, 5 had metastatic or multifocal lesions and 15 had single sites of disease. Comparative evaluation included morphological imaging with CT and functional imaging with (68)Ga-DOTA-TOC PET and (18)F-DOPA PET. The imaging results were analysed on a per-patient and a per-lesion basis. The maximum standardized uptake value (SUVmax) of each functional imaging modality in concordant tumour lesions was measured.

Results: Compared with anatomical imaging, (68)Ga-DOTA-TOC PET and (18)F-DOPA PET each had a per-patient and per-lesion detection rate of 100% in nonmetastatic extra-adrenal PGL. However, in metastatic or multifocal disease, the per-lesion detection rate of (68)Ga-DOTA-TOC was 100% and that of (18)F-DOPA PET was 56.0%. Overall, (68)Ga-DOTA-TOC PET identified 45 lesions; anatomical imaging identified 43 lesions, and (18)F-DOPA PET identified 32 lesions. The overall per-lesion detection rate of (68)Ga-DOTA-TOC PET was 100% (McNemar, P < 0.5), and that of (18)F-DOPA PET was 71.1% (McNemar, P < 0.001). The SUVmax (mean ± SD) of all 32 concordant lesions was 67.9 ± 61.5 for (68)Ga-DOTA-TOC PET and 11.8 ± 7.9 for (18)F-DOPA PET (Mann-Whitney U test, P < 0.0001).

Conclusion: (68)Ga-DOTA-TOC PET may be superior to (18)F-DOPA PET and diagnostic CT in providing valuable information for pretherapeutic staging of extra-adrenal PGL, particularly in surgically inoperable tumours and metastatic or multifocal disease.

Titel:	A retrospective comparison between 68Ga-DOTA-TOC PET/CT and 18F-DOPA PET/CT in patients with extra-adrenal paraganglioma.
Autor/in / Beteiligte Person:	Kroiss, A ; Putzer, D ; Frech, A ; Decristoforo, C ; Uprimny, C ; Gasser, RW ; Shulkin, BL ; Url, C ; Widmann, G ; Prommegger, R ; Sprinzl, GM ; Fraedrich, G ; Virgolini, IJ
Link:	Full Text Finder (Volltext)
Zeitschrift:	European journal of nuclear medicine and molecular imaging, Jg. 40 (2013-12-01), Heft 12, S. 1800-8
Veröffentlichung:	Berlin : Springer-Verlag Berlin, 2002-, 2013
Medientyp:	academicJournal
ISSN:	1619-7089 (electronic)
DOI:	10.1007/s00259-013-2548-y
Schlagwort:	Adult Aged Female Humans Male Middle Aged Retrospective Studies Young Adult Dihydroxyphenylalanine analogs & derivatives Multimodal Imaging methods Octreotide analogs & derivatives Organometallic Compounds Paraganglioma, Extra-Adrenal diagnostic imaging Positron-Emission Tomography methods Tomography, X-Ray Computed methods
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Publication Type: Comparative Study; Journal Article Language: English [Eur J Nucl Med Mol Imaging] 2013 Dec; Vol. 40 (12), pp. 1800-8. <i>Date of Electronic Publication: </i>2013 Sep 27. MeSH Terms: Organometallic Compounds* ; Dihydroxyphenylalanine / analogs & derivatives ; Multimodal Imaging / methods ; Octreotide / analogs & derivatives ; Paraganglioma, Extra-Adrenal / diagnostic imaging ; Positron-Emission Tomography / methods ; Tomography, X-Ray Computed / methods ; Adult ; Aged ; Female ; Humans ; Male ; Middle Aged ; Retrospective Studies ; Young Adult Comments: Comment in: Eur J Nucl Med Mol Imaging. 2013 Dec;40(12):1797-9. (PMID: 24072348) References: Eur J Nucl Med Mol Imaging. 2013 Apr;40(4):514-23. (PMID: 23291643) ; Horm Metab Res. 2012 May;44(5):367-72. (PMID: 22399235) ; Eur J Nucl Med Mol Imaging. 2003 May;30(5):689-94. (PMID: 12618904) ; J Clin Endocrinol Metab. 2009 Dec;94(12):4757-67. (PMID: 19864450) ; Q J Nucl Med. 1996 Dec;40(4):365-71. (PMID: 9050342) ; Endocr Pathol. 2008 Winter;19(4):207-8. (PMID: 18991024) ; J Nucl Med. 1996 Jan;37(1):32-7. (PMID: 8543997) ; Nucl Med Commun. 2007 Nov;28(11):870-5. (PMID: 17901771) ; Nucl Med Commun. 2011 Jul;32(7):575-82. (PMID: 21471850) ; J Clin Endocrinol Metab. 2003 Nov;88(11):5150-7. (PMID: 14602742) ; JAMA. 2000 Dec 20;284(23):3043-5. (PMID: 11122593) ; Neuroendocrinology. 2009;90(2):167-83. (PMID: 19077417) ; Fam Cancer. 2005;4(1):61-8. (PMID: 15883712) ; J Nucl Med. 2007 Apr;48(4):508-18. (PMID: 17401086) ; Eur J Nucl Med Mol Imaging. 2012 Dec;39(12):1977-95. (PMID: 22926712) ; Clin Nucl Med. 2013 Dec;38(12):e458-62. (PMID: 23486329) ; Eur J Nucl Med. 1998 Jan;25(1):79-83. (PMID: 9396878) ; J Nucl Med. 2008 Oct;49(10):1613-9. (PMID: 18794260) ; Int J Rad Appl Instrum A. 1990;41(3):275-81. (PMID: 2158953) ; Eur J Nucl Med Mol Imaging. 2011 May;38(5):865-73. (PMID: 21279352) ; Q J Nucl Med Mol Imaging. 2010 Feb;54(1):68-75. (PMID: 20168288) ; J Clin Oncol. 2007 Jun 1;25(16):2262-9. (PMID: 17538171) ; Eur J Nucl Med Mol Imaging. 2012 Jul;39(7):1144-53. (PMID: 22358431) ; Eur J Nucl Med. 1994 Mar;21(3):239-53. (PMID: 8200393) ; J Nucl Med. 2012 Feb;53(2):264-74. (PMID: 22302963) ; J Nucl Med. 2008 Aug;49(8):1232-7. (PMID: 18632829) Substance Nomenclature: 0 (Ga(III)-DOTATOC) ; 0 (Organometallic Compounds) ; 2C598205QX (fluorodopa F 18) ; 63-84-3 (Dihydroxyphenylalanine) ; RWM8CCW8GP (Octreotide) Entry Date(s): Date Created: 20130928 Date Completed: 20140610 Latest Revision: 20211021 Update Code: 20240513

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

A retrospective comparison between 68Ga-DOTA-TOC PET/CT and 18F-DOPA PET/CT in patients with extra-adrenal paraganglioma.